Tumors induce immune tolerance through activation of β-catenin/TCF4 signaling in dendritic cells: A novel therapeutic target for cancer immunotherapy

Amol Suryawanshi, Santhakumar Manicassamy

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Tumors promote immune suppression and dendritic cells (DCs) play a key role in this. However, signaling networks that program DCs to induce immune suppression are unknown. In our recent study, we showed that tumors activate β-catenin/TCF4 in DCs programming them to a regulatory state, which promotes T regulatory responses while suppresses effector T cell responses. Thus, targeting DCs-β-catenin pathway represents a promising target for anticancer immunotherapy.

Original languageEnglish (US)
JournalOncoImmunology
Volume4
Issue number12
DOIs
StatePublished - Dec 2 2015

Keywords

  • Wnt
  • cancer immunotherapy
  • dendritic cells
  • immune suppression
  • regulatory T cells
  • retionic acid
  • β-catenin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Tumors induce immune tolerance through activation of β-catenin/TCF4 signaling in dendritic cells: A novel therapeutic target for cancer immunotherapy'. Together they form a unique fingerprint.

  • Cite this